T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial

The Lancet

Volumn 385, Issue 9967, 2015, Pages 517-528

  Lee, Daniel W ^a   Kochenderfer, James N ^b   Stetler Stevenson, Maryalice ^c   Cui, Yongzhi K ^a   Delbrook, Cindy ^a   Feldman, Steven A ^c   Fry, Terry J ^a   Orentas, Rimas ^a   Sabatino, Marianna ^a   Shah, Nirali N ^a   Steinberg, Seth M ^d   Stroncek, Dave ^a   Tschernia, Nick ^e   Yuan, Constance ^c   Zhang, Hua ^a   Zhang, Ling ^a   Rosenberg, Steven A ^c   Wayne, Alan S ^f,g   Mackall, Crystal L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Experimental Transplantation and Immunology Branch   (United States)

^c Laboratory of Pathology   (United States)

^d Surgery Branch   (United States)

^e Clinical Center   (United States)

^f UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^g CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD28 ANTIGEN; CREATINE KINASE; CYCLOPHOSPHAMIDE; FLUDARABINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; AUTOTRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CD19 CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; CELL ENGINEERING; CELL TRANSPLANTATION; CHILD; CORRELATIONAL STUDY; CREATINE KINASE BLOOD LEVEL; CYTOKINE RELEASE SYNDROME; DYSPHASIA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTE; LUNG EDEMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY FAILURE; SCHOOL CHILD; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOPLASTIN TIME; TREMOR; YOUNG ADULT; BIOLOGICAL THERAPY; CHIMERA; CLINICAL TRIAL; COHORT ANALYSIS; IMMUNOLOGY; INFANT; LYMPHOMA, NON-HODGKIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD19; CELL- AND TISSUE-BASED THERAPY; CHILD; CHILD, PRESCHOOL; CHIMERA; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT; LYMPHOMA, NON-HODGKIN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923019006     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61403-3     Document Type: Article

References (34)

1. SP Hunger, X Lu, M Devidas et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group J Clin Oncol 30 2012 1663 1669
2. LL Robison Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age Hematology Am Soc Hematol Educ Program 2011 238 242 10.1182/asheducation-2011.1.238
3. D Pulte, A Gondos, H Brenner Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century Blood 113 2009 1408 1411
4. D Pulte, L Jansen, A Gondos the GEKID Cancer Survival Working Group Survival of adults with acute lymphoblastic leukemia in Germany and the United States PLoS One 9 2014 e85554
5. SJ Forman, JM Rowe The myth of the second remission of acute leukemia in the adult Blood 121 2013 1077 1082
6. MJ Burke, N Gossai, JE Wagner et al. Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 19 2013 138 142
7. W Leung, D Campana, J Yang et al. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia Blood 118 2011 223 230
8. DW Lee, DM Barrett, C Mackall, R Orentas, SA Grupp The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer Clin Cancer Res 18 2012 2780 2790
9. JN Kochenderfer, ME Dudley, SA Feldman et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells Blood 119 2012 2709 2720
10. JN Kochenderfer, WH Wilson, JE Janik et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 2010 4099 4102
11. DL Porter, BL Levine, M Kalos, A Bagg, CH June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
12. RJ Brentjens, I Rivière, JH Park et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 118 2011 4817 4828
13. ML Davila, I Riviere, X Wang et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia Sci Transl Med 6 2014 224ra25
14. SA Grupp, M Kalos, D Barrett et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 2013 1509 1518
15. RJ Brentjens, ML Davila, I Riviere et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 2013 177ra38
16. US Food and Drugs Administration Guidance for industry: gene therapy clinical trials - observing participants for delayed adverse events http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ (accessed July 18, 2014).
17. B Tumaini, DW Lee, T Lin et al. Simplified process for the production of anti-CD19-CAR-engineered T cells Cytotherapy 15 2013 1406 1415
18. JN Kochenderfer, SA Feldman, Y Zhao et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J Immunother 32 2009 689 702
19. BD Cheson, B Pfistner, ME Juweid the International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
20. B Jena, S Maiti, H Huls et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials PLoS One 8 2013 e57838
21. M Kalos, BL Levine, DL Porter et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
22. DR Schultz, PI Arnold Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen Semin Arthritis Rheum 20 1990 129 147
23. MB Pepys, GM Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812
24. DW Lee, R Gardner, DL Porter et al. Current concepts in the diagnosis and management of cytokine release syndrome Blood 124 2014 188 195
25. CR Cruz, KP Micklethwaite, B Savoldo et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study Blood 122 2013 2965 2973
26. J Westermann, R Pabst Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 11 1990 406 410
27. S Jeha, V Gandhi, KW Chan et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia Blood 103 2004 784 789
28. S Jeha, PS Gaynon, BI Razzouk et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia J Clin Oncol 24 2006 1917 1923
29. CH Pui, SC Howard Current management and challenges of malignant disease in the CNS in paediatric leukaemia Lancet Oncol 9 2008 257 268
30. MS Topp, N Gökbuget, G Zugmaier et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL Blood 120 2012 5185 5187
31. W Haso, DW Lee, NN Shah et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia Blood 121 2013 1165 1174
32. M Hegde, A Corder, KK Chow et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma Mol Ther 21 2013 2087 2101
33. RA Morgan, JC Yang, M Kitano, ME Dudley, CM Laurencot, SA Rosenberg Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
34. JN Kochenderfer, SA Rosenberg Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors Nat Rev Clin Oncol 10 2013 267 276